Grateful for Acumen Pharmaceuticals, Inc. and Daniel O'Connell for their continued efforts in advancing human health and keeping Charlottesville on the map in this important fight!
We are thrilled to extend our collaboration with Lonza to enable the potential future commercial launch of?sabirnetug, our next-generation investigational treatment for Alzheimer’s disease that targets toxic soluble amyloid beta oligomers. Lonza will now manufacture cGMP drug product at their state-of-the-art facility in Visp, Switzerland for ongoing and future clinical phases and support our potential commercial launch of sabirnetug. They will also provide quality control and stability testing. Learn more about our collaboration in today’s press release: https://lnkd.in/gGSTffYy #AlzheimersDisease #ClinicalTrials #Lonza #AcumenPharmaceuticals